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Rapidly identifying likely Ebola patients is difficult because 
of a broad case definition, overlap of symptoms with com-
mon illnesses, and lack of rapid diagnostics. However, 
rapid identification is critical for care and containment of 
contagion. We analyzed retrospective data from 252 Ebola-
positive and 172 Ebola-negative patients at a Sierra Leone 
Ebola treatment center to develop easy-to-use risk scores, 
based on symptoms and laboratory tests (if available), to 
stratify triaged patients by their likelihood of having Ebola 
infection. Headache, diarrhea, difficulty breathing, nausea/
vomiting, loss of appetite, and conjunctivitis comprised the 
symptom-based score. The laboratory-based score also in-
cluded creatinine, creatine kinase, alanine aminotransfer-
ase, and total bilirubin. This risk score correctly identified 
92% of Ebola-positive patients as high risk for infection; 
both scores correctly classified >70% of Ebola-negative 
patients as low or medium risk. Clinicians can use these 
risk scores to gauge the likelihood of triaged patients having 
Ebola while awaiting laboratory confirmation.
The 2014–2016 West Africa Ebola virus epidemic, un-paralleled in spread for this disease, quickly over-
whelmed the health systems of the 3 most affected countries 
(1). Ebola virus disease (EVD) can be difficult to initially 
identify even in a well-functioning health system because its 
early symptoms can closely mimic those of other common 
illnesses, such as malaria, typhoid, viral illness, and gastro-
enteritis (2,3). Thus, in an already weakened health system, 
the task of quickly but correctly identifying and isolating 
Ebola patients before laboratory test results are available is 
particularly challenging. This fact can result in missed op-
portunities to isolate infectious patients (through incomplete 
screening sensitivity) and expose non-Ebola patients to nos-
ocomial infection (through incomplete specificity).
Currently, the most common laboratory test to identify 
EVD relies on a reverse transcription PCR (2), which is 
not a rapid point-of-care (POC) test but instead requires 
substantial laboratory infrastructure. In the West Africa 
outbreak, patient blood samples were typically sent to off-
site laboratories set up through the international response. 
Although the test itself can be done in hours, the round trip 
from a health facility to the laboratory often took >3 days, 
especially during the peak of the epidemic (4). Although a 
few rapid POC EVD diagnostics were developed and field-
tested during this outbreak, they are not yet ready for wide-
spread commercial use (5,6).
In lieu of rapid POC EVD tests to identify EVD-pos-
itive cases, a standardized EVD case definition from the 
World Health Organization (WHO) was used during the 
epidemic as the primary tool for initially identifying po-
tential EVD patients (7). Because false negatives for EVD 
put patients and their communities at great risk, this case 
definition is broad (high sensitivity/low specificity) (8). A 
broad case definition is also useful for epidemic surveil-
lance. Patients meeting the case definition, which is based 
on symptoms and potential exposure, were sent to holding 
centers for EVD testing and isolation. However, the broad 
case definition meant that negative and positive EVD pa-
tients were mixed together, often for days, until their test 
results were available and treatment facilities had beds for 
the positive patients. Although some holding centers tried 
to separate suspect patients based on wet (i.e., diarrhea or 
vomiting) versus dry symptoms, this crude separation can 
expose Ebola-negative patients, particularly those with wet 
symptoms, to a higher risk of nosocomial infection.
Thus, an Ebola risk score that rapidly further differ-
entiates the likelihood of Ebola infection beyond the case 
definition could be beneficial. Risk scores based on non-
invasive information, such as demographic characteristics 
and symptoms, are practical tools for diagnostic predic-
tion models because the predictors are comparatively sim-
ple to ascertain. Such risk scores are especially useful in 
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resource-limited settings because a range of persons, from 
community health workers to clinicians, can quickly obtain 
the necessary patient information (9,10). Symptom-based 
risk scores have been used to identify patients at higher 
risk of various diseases (e.g., pulmonary tuberculosis, gas-
tric cancer) or outcomes (e.g., predicting mortality in sick 
children) in resource-limited settings (11–13). However, 
symptom-based risk scores are limited by the accuracy 
of symptom reporting and the predictive power of those 
symptoms (14,15). Additional variables, such as laboratory 
tests, can improve the accuracy of risk scores, at the cost of 
less versatility (16,17). One solution has been to develop 
risk scores with optional additional variables to improve 
accuracy when those variables can be ascertained (13). As 
rapid POC laboratory devices such as the Piccolo Xpress 
(Abaxis, Inc., Union City, CA, USA) and i-STAT (Abbott 
Point of Care, Princeton, NJ, USA) analyzers have become 
more common even in low-income settings (18), adding 
optional laboratory tests to risk scores has become feasible.
We analyzed data from the Kerry Town Ebola treat-
ment center (ETC) in Sierra Leone to develop 2 Ebola 
risk scores. The first uses symptom data and the second 
incorporates biochemistry laboratory tests to improve pre-
diction accuracy. The goal of these risk scores is to supple-
ment the broad WHO case definition by further separating 
triaged patients on the basis of their likelihood of being 
EVD positive.
Methods
Study Design and Patient Population
This research consisted of a retrospective cohort study 
of deidentified data on patients from November 5, 2014, 
through March 31, 2015, at the Kerry Town ETC in Si-
erra Leone. This 80-bed ETC, based in the Western Area 
Rural district, was operated by Save the Children Interna-
tional in partnership with the United Kingdom and Sierra 
Leone governments.
The patient population at the ETC consisted of pa-
tients with suspected or confirmed EVD, mostly from the 
nearby Western Area Urban and Western Area Rural dis-
tricts. The ETC featured dry and wet wards for suspected 
Ebola patients (suspect wards) without a prior EVD test 
result and treatment wards for those confirmed to have 
EVD. Patients already confirmed to have EVD at previous 
holding centers were admitted directly to the confirmed 
wards. Suspected patients who met the admission crite-
ria at triage were admitted to suspect wards while await-
ing their EVD test results. All confirmed and suspected 
patients received on-site EVD tests, with results in <24 
hours from admission. Suspected patients who tested pos-
itive were transferred to the confirmed wards; those test-
ing negative were discharged or retested for up to 3 days 
before being discharged. All ETC patients with informa-
tion recorded on basic demographic details and baseline 
symptoms were included in this study. The Sierra Leone 
Ethics and Scientific Review Committee and the London 
School of Hygiene and Tropical Medicine in the United 
Kingdom granted ethical approval for this study.
Data Collection
We used only data routinely collected for patient care on 
standardized clinical record forms. Referred patients often 
arrived with forms from their previous holding centers and/
or a standardized case investigation form containing demo-
graphic and epidemiologic characteristics, as well as symp-
toms at admission (7).
We transcribed data from the paper clinical records 
into electronic format using Excel version 14.5.2 (Micro-
soft, Redmond, WA, USA). We then imported these data 
into Stata version 12 (https://www.stata.com) for statisti-
cal analyses.
Data Input and Cleaning
The outcome measure was EVD, confirmed by the on-site 
Public Health England laboratory using a reverse transcrip-
tion PCR. For potential predictors of positive EVD test 
outcomes, we investigated 14 commonly recorded symp-
toms and analyzed these as binary variables. We recorded a 
symptom as present if it was checked as present on the case 
investigation, triage, or baseline admission forms. In an 
additional analysis, we included among the potential pre-
dictors 13 biochemistry laboratory tests performed by the 
on-site UK Ministry of Defense laboratory using a Piccolo 
Xpress device, which can yield rapid results (≈12 minutes) 
at the point of care. For the purpose of our analysis, we 
converted the test results into categorical variables based 
on low and high abnormal test ranges.
We performed multiple imputation by chained equa-
tions (19) for missing laboratory results based on the 
missing at random assumption. We used predictive mean 
matching with 20 iterations and included all the symp-
toms, the outcome variable, age, and sex as factors for 
the imputation.
Model Building
We built our symptom-based predictive model as follows. 
First, we performed univariable logistic regressions of each 
symptom against EVD outcome. We retained any symptom 
that had a p value of <0.40 for further analysis. We chose this 
lenient cutoff to balance the poor performance of diagnos-
tic prediction models when relying solely on p values (20) 
against the need to reduce the number of symptom combi-
nations being investigated. We used 10-fold cross valida-
tion to assess the best out-of-sample fit for all combinations 
of symptoms retained in the analysis after the univariable 
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analysis. We chose to use cross-validation because com-
monly used stepwise procedures for model selection have 
come under widespread criticism for several reasons, includ-
ing overfitting, p value exaggeration, and biased coefficient 
estimates (21,22). Moreover, we were interested in selecting 
symptom combinations with better out-of-sample perfor-
mance for use outside our patient dataset. 
We used standard methods for cross-validation (23). 
First, we randomly partitioned the dataset into 10 equal 
subsamples. We then ran multivariable logistic regressions 
of each symptom combination against EVD outcome on 
90% of the data (i.e., the training dataset), and used the re-
sults to predict the probability of EVD for each observation 
in the remaining 10% of the dataset (i.e., the validation da-
taset). For each symptom combination, we created receiver 
operating characteristic (ROC) curves and calculated the 
area under the curve (AUC) for each of the 10 validation 
datasets. The AUC is a standard measure of accuracy of 
test performance, with 1 indicating a perfect model and 0.5 
indicating no better than random guessing (24). We took 
the median of the 10 AUCs as the overall goodness of fit 
for each candidate symptom combination model. We chose 
the best-fit model based on which model had the highest 
out-of-sample median AUC.
Development of Risk Score
We used previously established methods (13,25) to de-
velop an easy-to-use Ebola symptom-based risk (ESR) 
score using the selected model. First, we ran a multivari-
able logistic regression of the model against EVD. We then 
assigned integer scores to individual symptoms based on 
their regression coefficients, with a score of 1 for coeffi-
cients <1 and a score of 2 for coefficients >1, while keep-
ing the original sign. We calculated a patient’s overall ESR 
score by adding the integer scores for the symptoms present 
in that patient. We then mapped the number of patients by 
true EVD status at each integer level of the ESR score. We 
evaluated the score by calculating the sensitivity, specific-
ity, positive predictive value (PPV), and negative predic-
tive value (NPV) for each level by designating all patients 
below that level as EVD negative and those at or above it 
as EVD positive. Finally, we determined low-, medium-, 
and high-risk categories by identifying risk thresholds that 
first maximized the number of true EVD positives in the 
high-risk category and minimized them in the low-risk cat-
egory, and then best limited the true EVD negatives in the 
high-risk category.
Adding Laboratory Tests to the Ebola Risk Score
We performed additional analysis on patients with >1 
non-Ebola laboratory result. We used univariable logis-
tic regressions of the categorical laboratory test values 
against EVD outcome to retain laboratory tests with a p 
value of <0.40. For each possible combination of tests, we 
performed a multivariable logistic regression, this time ad-
justing for symptoms in the ESR score, and assigned an 
integer score to the laboratory tests using the same rule as 
that for the ESR score. We then used the net reclassification 
improvement (NRI) metric (26) and reclassification tables 
(27) to evaluate which laboratory test combinations best 
improved the symptom-based Ebola risk score. Of the 10 
models with the highest NRI, we chose the model with the 
largest summed improvement in categorizing EVD-pos-
itive and EVD-negative patients within the high-risk cat-
egory of the ESR score. We chose this metric to prioritize 
an improvement in sensitivity while not overly sacrificing 
specificity. We added the individual laboratory test integer 
scores to the ESR score for a final Ebola symptom- and 
laboratory-based (ESLR) score. To determine whether the 
ESLR score was an improvement over the ESR score, we 
visually compared their ROC curves and tested the statisti-
cal significance of the difference in AUCs (28).
Internal Validation
We performed internal validation of our risk scores using 
the bootstrap method to correct for overoptimism (29). We 
drew 1,000 bootstrap samples with replacement and calcu-
lated the AUC for the best model in each sample and the 
corresponding AUC in the full dataset. We then took the 
difference of these mean AUCs and corrected for overop-
timism by subtracting this total from the AUC of our risk 
score. We performed this process separately for the ESR 
and ESLR scores.
Results
Of the 456 patients who were admitted to the Kerry Town 
ETC with suspected or confirmed EVD, we excluded 32 
patients (7.0%): 31 had no baseline forms or minimal/no 
symptoms recorded, and 1 died before an EVD test could 
be conducted. Of the remaining 424 patients, samples from 
252 tested positive for EVD and samples from 172 tested 
negative. Basic demographic characteristics and outcomes 
of the patients are provided in Table 1, and frequencies of 
clinical symptoms and the univariable logistic regression 
results by EVD status are shown in Table 2. The 10 symp-
toms with univariable p values <0.40 gave rise to 1,024 
candidate symptom combinations for final model selection.
Using the cross-validation model selection, we ob-
tained the best out-of-sample fit with a 6-symptom model 
comprising headache, diarrhea, difficulty breathing, nausea/
vomiting, loss of appetite, and conjunctivitis. The median 
out-of-sample AUC for this model was 0.84 (interquartile 
range [IQR] 0.79–0.86). The validation analysis yielded 
a correction of 0.012, resulting in an internally validated 
AUC of 0.83 for the ESR score, which is considered excel-
lent discrimination (30).
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We found >1 non-EVD laboratory result for 309 pa-
tients. Of these, the percentage of missing laboratory re-
sults ranged from 5.1% for glucose to 15.2% for total 
bilirubin and aspartate aminotransferase. Visual inspection 
of the observed and imputed data suggested that the im-
putation worked well (online Technical Appendix Figures 
1–13, https://wwwnc.cdc.gov/EID/article/23/11/17-0171-
Techapp1.pdf). We excluded glucose and albumin because 
of p values >0.40 and thus retained 11 laboratory tests for 
consideration (online Technical Appendix Table 1).
According to the NRI and reclassification tables (on-
line Technical Appendix Table 2), the best combination of 
additional laboratory tests was creatinine, creatine kinase 
(CK), alanine aminotransferase (ALT), and total bilirubin. 
The median out-of-sample AUC for the ESLR score was 
0.91 (IQR 0.89–0.92). The internally validated AUC for 
the ESLR score was 0.90, which is considered outstanding 
discrimination (30).
Table 3 shows the multivariable model results, as well 
as the assigned integer scores for individual symptom and 
laboratory tests. An individual patient’s ESR score could 
range from –3 to +5 and the ESLR score from –4 to +9. The 
trade-off between sensitivity and specificity for each score 
level was generally better for the ESLR than for the ESR 
score (Table 4). The difference in the AUC of the ROC 
indicated that the ESLR score was a significant improve-
ment (p<0.001) over the ESR score (Figure 1).
We classified the ESR and ESLR scores as low risk if 
negative, medium risk if 0, and high risk if positive. Us-
ing the ESR score, we categorized 71.8% (95% CI 66.2%–
77.4%) of EVD-positive patients as high risk and 14.3% 
(95% CI 10.0%–18.6%) as low risk (Figure 2, panel A). 
The ESLR score was more discriminant, with 91.9% (95% 
CI 87.8%–96.0%) of EVD positive patients considered 
high risk and 4.6% (95% CI 1.5%–7.7%) low risk using 
this score. Similar percentages of EVD-negative patients 
were categorized as low risk with the ESR (43.0%, 95% 
CI 35.6%–50.4%) versus ESLR (45.6%, 95% CI 37.2%–
54.0%) scores (Figure 2, panel B). The ESR score per-
formed better among EVD-negative patients classified as 
high risk, but not significantly so, with 23.8% (95% CI 
17.4%–30.2%) for the ESR score compared with 29.4% 
(95% CI 21.7%–37.1%) for the ESLR score.
Discussion
We developed Ebola risk scores, based on reported symp-
toms and, optionally, complementary POC laboratory tests, 
to help categorize suspected Ebola patients into low-, me-
dium-, and high-risk categories. These risk scores can be 
used after applying the case definition to further separate 
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Table 1. Basic characteristics and outcomes of patients by EVD status at the Kerry Town ETC, Sierra Leone, 2014–2015* 
Characteristic EVD negative, n = 172 EVD positive, n = 252 
Sex, no. (%)   
 F 69 (40.1) 144 (57.1) 
 M 103 (59.9) 108 (42.9) 
Median age, y (IQR) 27 (20–40) 25 (14–35) 
Mode of arrival to facility, no. (%)   
 Ambulance (referral) 95 (55.2) 242 (96.0) 
 Walk-in 77 (44.8) 10 (4.0) 
Median days between onset of symptoms and admission (IQR) 3 (2–6) 3 (2–5) 
Median length of stay at ETC, d (IQR) 1 (1–2) 6 (3–11) 
Deaths, no. (case fatality ratio, %) 12 (7.0) 107 (42.5) 
*ETC, Ebola treatment center; EVD, Ebola virus disease; IQR, interquartile range.  
 
 
Table 2. Patient clinical symptoms by Ebola status at the Kerry Town ETC, Sierra Leone, 2014–2015* 
Univariable logistic regression 
Coefficient (95% CI) p value 
Fever† 165 (95.9) 230 (91.3) 0.81 (1.69 to 0.06) 0.068 
Headache† 132 (76.7) 161 (63.9) 0.62 (1.06 to 0.19) 0.005 
Fatigue 158 (91.9) 226 (89.7) 0.26 (0.94 to 0.42) 0.452 
Joint/muscle pain† 146 (84.9) 182 (72.2) 0.77 (1.27 to 0.27) 0.003 
Diarrhea† 68 (39.5) 165 (65.5) 1.06 (0.66 to 1.47) <0.001 
Bleeding 20 (11.6) 27 (10.7) 0.09 (0.71 to 0.52) 0.769 
Difficulty breathing† 93 (54.1) 48 (19.1) 1.61 (2.04 to 1.18) <0.001 
Nausea/vomiting† 95 (55.2) 173 (68.7) 0.57 (0.17 to 0.98) 0.005 
Abdominal pain 111 (64.5) 162 (64.3) 0.01 (0.42 to 0.39) 0.958 
Hiccups† 39 (22.7) 42 (16.7) 0.38 (0.87 to 0.10) 0.124 
Swallowing pain 56 (32.6) 90 (35.7) 0.14 (0.27 to 0.55) 0.502 
Loss of appetite/anorexia† 156 (90.7) 174 (69.1) 1.47 (2.05 to 0.90) <0.001 
Conjunctivitis† 44 (25.6) 122 (48.4) 1.00 (0.58 to 1.43) <0.001 
Rash† 6 (3.5) 16 (6.4) 0.63 (0.33 to 1.59) 0.199 
*ETC, Ebola Treatment Center; EVD, Ebola virus disease. 
†p<0.40 and thus retained to construct candidate symptom combinations. 
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suspected Ebola patients at triage based on their likelihood 
of having EVD.
The ESR and ESLR scores generally performed 
well. Of suspected patients whose specimens tested 
positive, >70% were categorized as high risk by the 
ESR score and >90% as high risk by the ESLR score. 
This result means that most true-positive patients could 
have been correctly separated from those who ultimately 
tested negative. About one quarter of EVD-negative pa-
tients were classified as high risk, but this trade-off was 
necessary to ensure that most true positives were cor-
rectly deemed high risk. Unfortunately, we do not have 
true diagnoses available for these non-Ebola patients to 
determine whether some illnesses were more associated 
with a high-risk classification than others. Compared 
with our results, we found low specificity (4.7%, 95% 
CI 1.5%–7.8%) and NPV (18.2%, 95% CI 6.8%–29.6%) 
when applying the symptom component of the WHO 
case definition (inexplicable bleeding or fever plus 3 of 
10 symptoms) (31) to our patients. Both the ESR and 
ESLR scores can substantially improve upon these crite-
ria. For example, using the threshold of >2 for the ESLR 
score resulted in 81.6% (95% CI 75.1%–88.1%) speci-
ficity and 80.4% (95% CI 73.8%–87.0%) NPV.
Although laboratory test results are generally of high-
er quality than self-reported symptoms, we included them 
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Table 3. Factors included in ESR and ESLR scores to determine risk for infection in suspected Ebola patients* 
Factor Coefficient (95% CI) from multivariable model† p value Score value 
Symptoms, for ESR and ESLR scores 
 Conjunctivitis 1.44 (0.93 to 1.95) <0.001 +2 
 Diarrhea 1.11 (0.60 to 1.61) <0.001 +2 
 Nausea/vomiting 0.78 (0.24 to 1.31) 0.005 +1 
 Headache 0.45 (0.98 to 0.09) 0.103 1 
 Difficulty breathing 1.60 (2.11 to 1.10) <0.001 1 
 Loss of appetite 1.90 (2.60 to 1.20) <0.001 1 
Laboratory tests if available, for ESLR score only 
 Alanine transaminase >48 U/L 3.83 (2.67 to 5.00) <0.001 +2 
 Creatine kinase >380 U/L 1.78 (0.73 to 2.84) 0.001 +2 
 Creatinine >106 μmol/L 1.15 (2.21 to 0.09) 0.033 1 
 Total bilirubin >27 μmol/L 1.81 (3.24 to 0.39) 0.012 1 
*ESLR, Ebola symptom- and laboratory-based risk; ESR, Ebola symptom-based risk.  
†Laboratory tests have been adjusted for the symptom predictors. Coefficient values are before normalization. 
 
 
Table 4. Sensitivity, specificity, positive predictive value, and negative predictive value of ESR and ESLR scores to determine risk for 
infection in suspected Ebola patients* 
Score % EVD negative % EVD positive Sensitivity† (95% CI) Specificity† (95% CI) PPV† (95% CI) NPV† (95% CI) 
ESR score, range 3 to +5 
 3 8 0 100 (100–100) 0 (0–0) 59 (55–64) NA 
 2 16 4 100 (100–100) 8 (4–12) 61 (57–66) 100 (100–100) 
 1 19 10 96 (94–98) 24 (18–31) 65 (60–70) 81 (70–91) 
 0 33 14 86 (81–90) 43 (36–50) 69 (64–74) 67 (59–76) 
 1 13 19 72 (66–77) 76 (70–83) 82 (76–87) 65 (58–71) 
 2 6 24 53 (47–59) 89 (84–94) 88 (82–93) 56 (50–62) 
 3 5 21 29 (23–35) 95 (92–98) 90 (84–97) 48 (43–53) 
 4 0 7 8 (5–11) 100 (100–100) 100 (100–100) 43 (38–47) 
 5 0 1 1 (0–3) 100 (100–100) 100 (100–100) 41 (36–46) 
ESLR score, range 4 to +9 
 4 1 0 100 (100–100) 0 (0–0) 56 (50–62) NA 
 3 10 1 100 (100–100) 1 (0–2) 56 (51–62) 100 (100–100) 
 2 16 1 99 (98–100) 10 (5–15) 59 (53–64) 93 (81–100) 
 1 19 3 99 (97–100) 26 (19–34) 63 (57–69) 95 (88–100) 
 0 25 3 95 (92–99) 46 (37–54) 69 (63–75) 89 (81–96) 
 1 11 8 92 (88–96) 71 (63–78) 80 (74–85) 87 (81–94) 
 2 7 14 84 (79–90) 82 (75–88) 85 (80–91) 80 (74–87) 
 3 9 14 70 (63–77) 89 (84–94) 89 (84–94) 70 (63–77) 
 4 1 20 55 (48–63) 98 (95–100) 97 (94–100) 63 (57–70) 
 5 1 17 36 (29–43) 99 (97–100) 97 (93–100) 55 (48–61) 
 6 0 10 18 (13–24) 100 (100–100) 100 (100–100) 49 (43–55) 
 7 0 7 9 (4–13) 100 (100–100) 100 (100–100) 46 (41–52) 
 8 0 1 2 (0–4) 100 (100–100) 100 (100–100) 44 (39–50) 
 9 0 1 1 (0–3) 100 (100–100) 100 (100–100) 44 (39–50) 
*ESLR, Ebola symptom- and laboratory-based risk; ESR, Ebola symptom-based risk; EVD,  Ebola virus disease; NPV, negative predictive value; 
PPV,  positive predictive value.  
†Based on greater or equal to the score (e.g., sensitivity for a score of 0 means that those with a score of 0 or higher were considered to be EVD 
positive). 
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only as optional additions to our risk score, which permits 
better accuracy while retaining the versatility of using 
only the symptom-based score in places without neces-
sary laboratory equipment. The improvement with labora-
tory tests can be substantial; in our study, 21.3% of EVD-
positive patients were newly classified as high risk when 
using the ESLR score instead of the ESR score. With the 
rise of POC tests in low-resource settings, risk scores that 
rely on laboratory tests are becoming more feasible. For 
example, we included only laboratory tests that are avail-
able using the rapid POC Piccolo Xpress device, which 
was used at our site and by others during the West Africa 
Ebola outbreak (32,33).
Although risk scores have become a common tool for 
stratifying and predicting risk, we found only one previous 
study that developed a risk score for Ebola (34). That study, 
based on data from a Liberian ETC in 2014, was a notable 
first step for Ebola risk scores, but it did not include labo-
ratory tests and had a smaller sample size. This difference 
may explain why our ESR and ESLR scores appear to have 
better sensitivity/specificity trade-offs.
We were constrained by the amount and quality of pa-
tient data because the data were collected during a challeng-
ing emergency response and only essential clinical, epidemi-
ologic, and demographic information was collected for each 
patient. Thus, some data that may have improved our Ebola 
risk score, such as other symptoms or detailed exposure in-
formation, were unavailable. For example, we had to exclude 
exposure as a potential predictor because of questionable 
quality and large amounts of missing data for this variable.
Our study is based on a patient population at 1 treatment 
center; these patients may not be representative of the overall 
population of suspected Ebola cases in West Africa or in fu-
ture Ebola outbreaks. Additionally, the distribution of patient 
characteristics may be different at a general medical facility 
or outside of an epidemic. The small correction factor from 
the internal validation exercise suggests that our scores would 
work similarly in a different epidemic study population. Ideal-
ly, our Ebola risk score should be externally validated against 
data from a future outbreak or, if made available, from this 
one. Although other common Ebola strains have similar re-
ported symptoms to this Zaire strain (35), our scores should 
not be used for them without testing/validation. In general, the 
techniques presented here could be used to develop new risk 
scores for such strains or other hemorrhagic fevers. Given the 
good internal validation and the rare inclusion of high-quality 
POC laboratory tests, however, we believe that our work is a 
step toward having an accurate Ebola risk score.
Our risk scores cannot replace the WHO case defini-
tion or actual diagnostic testing. They can, however, help 
fill the gap between a broad case definition and an often-
lengthy diagnostic process, which is valuable for several 
reasons. First, our risk scores can be used to more accurate-
ly separate likely negative from likely positive Ebola pa-
tients after initial screening with the WHO case definition. 
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Figure 1. Receiver operating characteristic curves for ESR and 
ESLR scores to determine risk for infection in suspected Ebola 
patients.  ESLR, Ebola symptom- and laboratory-based risk; 
ESR, Ebola symptom-based risk.
Figure 2. Suspected Ebola patients categorized as high-, medium-, and low-risk by ESR and ESLR scores, Kerry Town Ebola treatment 
center, Sierra Leone, 2014–2015. A) EVD-positive patients; B) EVD-negative patients. ESLR, Ebola symptom- and laboratory-based 
risk; ESR, Ebola symptom-based risk. Numbers in parentheses indicate 95% CIs.
RESEARCH
For example, patients could be physically separated into 
low-, medium-, and high-risk suspect wards based on their 
risk score while awaiting Ebola test results. The higher-risk 
wards could then have further protections, such as addi-
tional barriers between patients or separation of wet and 
dry patients. This distinction is beneficial to both Ebola-
negative patients and their communities because it reduces 
the risk of nosocomial infection that could be spread back 
to the community. Second, Ebola is a rapidly progressing 
disease, with typically only 6 to 16 days between onset of 
symptoms and death (2). Therefore, more accurately iden-
tifying likely positive cases while awaiting test results can 
mean earlier focus on and treatment of true positives dur-
ing a response with limited resources. Third, with tempo-
rary Ebola holding and treatment centers now closed in 
West Africa, new cases there and elsewhere are likely to 
be screened at a wide range of places within the existing 
health system, from the community to local health centers 
to regional hospitals. When Ebola is rare, we still expect 
large numbers of patients to meet the WHO case definition 
because of the broad symptom list associated with EVD. 
An Ebola risk score can thus be useful in giving more pre-
cise information about risk to community health workers 
and clinicians. Finally, an advantage of using a risk score 
like ours is that, as the epidemic evolves, cutoffs for patient 
triage and categorization can be modified in real time (e.g., 
using Table 4) to reflect a changing emphasis on sensitivity 
vesus specificity.
Given the danger Ebola poses, classifying the risk of 
suspected Ebola patients is essential. Until a reliable rapid 
POC diagnostic for Ebola is readily available in low-re-
source settings, a flexible risk score that is easy to imple-
ment can be a useful tool for further triaging patients. Even 
though outbreaks of poorly understood but dangerous in-
fectious diseases will continue in the future, developing 
such risk scores can help inform the difficult choices that 
healthcare workers must make during these emergencies.
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